Latest news with #HeartMate3
Newsweek
30-04-2025
- Health
- Newsweek
Robotics in Health Care: A New Era of Precision and Possibility
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The future of health care is unfolding before our eyes, driven by an unprecedented fusion of robotics and artificial intelligence (AI). What was once speculative technology is now steadily reshaping patient care. Enhanced surgical precision and reduced complications are making lifesaving interventions more accessible. With global spending on surgical robotics projected to exceed $20.98 billion by 2030, and the AI health care market expected to reach $187 billion in the same year, advanced automation has transitioned from "nice to have" to an essential driver of modern medicine. Throughout the Middle East and beyond, health care institutions increasingly rely on robotic-assisted surgery, AI-powered diagnostics and intelligent hospital automation to enhance clinical outcomes and optimize operational efficiencies. From streamlined diagnostic workflows to predictive hospital management, robotics is rapidly altering the way care is delivered. This shift is exemplified by King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia, a global leader in using robotics to enhance patient care and operational efficiency. King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia is a global leader in using robotics to enhance patient care and operational efficiency. King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia is a global leader in using robotics to enhance patient care and operational efficiency. King Faisal Specialist Hospital & Research Centre Historically, cardiac procedures like heart transplants and artificial heart pump implantations were high-risk interventions requiring prolonged hospital stays. Now, fully robotic heart transplants can be completed in just 2.5 hours, substantially improving surgical efficiency and patient recovery. Likewise, the robotic-assisted implantation of the HeartMate 3 artificial heart pump has cut ICU stays from an average of 26 days to only four, dramatically reducing complications and redefining outcomes for patients once faced with daunting recovery paths. Yet, cardiac surgery is only one part of this larger transformation. Robotic systems are now advancing liver transplantation, neurosurgery and pediatric care, delivering unmatched precision in even the most complex medical interventions. Fully robotic liver transplantations, for example, illustrate how robotics can replace highly invasive methods, dramatically reducing post-operative complications and recovery times. Other breakthroughs, such as robotic-assisted pancreas transplants and retroperitoneal lymph node dissection, further demonstrate how robotic precision is making once-challenging surgeries safer and more successful. At KFSHRC alone, 1,127 robotic-assisted procedures were completed in 2024, underscoring how this approach has rapidly moved from a futuristic concept to a transformative reality in daily practice. Neurosurgical robotics similarly enhances the accuracy of brain and spinal procedures, minimizing human error in operations that demand sub-millimeter precision. Meanwhile, AI-powered soft robotics allows for highly flexible, adaptive instruments that reduce trauma during intricate interventions. Collectively, these developments point to robotics as a new standard of care—one that delivers superior outcomes for patients facing a wide range of serious conditions. The synergy of AI and robotics is also ushering in predictive, personalized medicine. AI-powered diagnostic tools deliver results 20 percent faster, improving pre-surgical planning and reducing human errors, while real-time analytics allow robotic systems to adapt mid-operation for unprecedented responsiveness. Concurrently, AI-driven virtual pathology services enhance diagnostic accuracy and free specialists to address the most complex cases. By integrating these capabilities, medicine is shifting from reactive to proactive, preventing complications before they arise and tailoring treatment to each patient's unique genetic and physiological profile. Robotic surgeries often have better outcomes for the patient including shorter recovery times. Robotic surgeries often have better outcomes for the patient including shorter recovery times. King Faisal Specialist Hospital and Research Centre Robotics are also transforming rehabilitation and physical therapy, where exoskeletons and AI-driven prosthetics are helping patients recover mobility with greater speed and effectiveness. Hospitals are integrating robotic automation in pharmacy management and supply chain logistics, improving medication dispensing accuracy and ensuring consistent inventory flow. These system-wide optimizations not only elevate patient safety but also reduce operational expenses, enabling health care providers to redirect resources where they are needed most. Another exciting frontier in robotic health care is nanomedicine, where microscopic robots are being developed to target cancerous cells, deliver drugs with extreme precision and even repair tissues at a cellular level. For instance, nanorobots smaller than blood cells are being designed to deliver medication directly to tumor sites, potentially revolutionizing cancer treatment by reducing severe side effects associated with traditional chemotherapy. This concept of "intelligent drug delivery" has shown promising results in preclinical trials, indicating a future where nanorobots could become integral to cancer treatment protocols. Simultaneously, the emergence of smart hospitals—digitized ecosystems integrating AI, IoT and robotic automation—is rapidly reshaping global health care delivery. With the global smart hospital market projected to reach $148 billion by 2029, hospitals worldwide are adopting technologies such as AI-powered virtual nursing assistants, robotic patient transport systems and automated drug administration systems, significantly enhancing hospital workflows and patient experiences. These digitized environments, characterized by centralized electronic health records (EHRs), automated patient monitoring and real-time data analytics, significantly enhance resource allocation and patient care delivery efficiency. Saudi Arabia has notably invested approximately $1.5 billion in digital health infrastructure, emphasizing the development of centralized EHRs, telemedicine capabilities and advanced analytics, which collectively drive greater efficiency and elevate health care standards across the nation, positioning Saudi Arabia among global leaders in smart health care innovation. Beyond clinical innovation, robotic-assisted surgery is making top-tier health care more accessible and cost-effective. In many medical centers, the cost of heart transplants has fallen by 40 percent compared to Western averages, boosting affordability without sacrificing quality. As medical tourism hubs adopt robotics, international patients gain access to advanced surgeries at lower costs, contributing to a 50 percent reduction in hospital stays, proven cost efficiency and patient satisfaction rates climbing to 92 percent. At KFSHRC alone, 1,127 robotic-assisted procedures were completed in 2024. At KFSHRC alone, 1,127 robotic-assisted procedures were completed in 2024. King Faisal Specialist Hospital & Research Centre As health care enters this new era, robotics and AI are poised to become cornerstones of modern medicine. However, responsible implementation is essential. Hospitals must ensure robotic technologies enhance—not replace—human expertise, bolstered by robust ethical frameworks and clear accountability measures. Equally vital is ongoing workforce development through structured training, simulation-based exercises and cross-disciplinary workshops. The Kingdom has taken a proactive stance, investing in AI training, medical education and simulation-based surgical programs. Through the Human Capability Development Program (HCDP) and expanded digital health certifications, the Kingdom is preparing its health care workforce for the future. This approach—combining infrastructure investment with human capability development positions Saudi Arabia as a leader in the future of AI-driven health care. Ultimately, in the race to health care robotics, success will be judged not by the sheer number of procedures performed, but by the lives saved. It falls to health care leaders to guide this transformation, ensuring that these remarkable innovations transcend technological achievement to truly improve lives and elevate the global standard of care. H.E. Dr. Majid Al Fayyadh is a member of the Newsweek CEO Circle, an invite-only executive community of subscribers.
Yahoo
05-03-2025
- Business
- Yahoo
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin
Cadrenal Therapeutics has entered a partnership with Abbott for the tecarfarin anticoagulation and haemocompatibility with left ventricular assist devices (TECH-LVAD) trial. With Abbott's support, Cadrenal aims to plan and execute the trial, which assesses the safety and efficacy of oral vitamin K antagonist, tecarfarin, in individuals with LVADs, under the partnership and data sharing agreement terms. The company will receive Abbott's insights from recent HeartMate 3 trials, including its support in designing the study, site recognition, trial awareness, and 'expertise' on the HeartMate 3 LVAD. Cadrenal Therapeutics CEO Quang Pham said: 'We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrolment efforts. 'Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3 LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years.' Abbott's mechanical circulatory support device, HeartMate 3 LVAD, is tailored for individuals with advanced heart failure. The device is used for both short- and long-term support in these patients. It features Full MagLev Flow technology in the pump, which is said to 'maintain' blood handling for decreasing complications as well as adverse events related to hemocompatibility. Cadrenal is focused on developing tecarfarin to offer a 'safer' anticoagulant alternative to warfarin for individuals with cardiac devices. Tecarfarin has gained orphan drug designation for advanced heart failure individuals who are implanted with LVADs, and fast track status for those with end-stage kidney disease and atrial fibrillation. "Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Mid East Info
27-01-2025
- Health
- Mid East Info
KFSHRC Heart Centre: A Leader in Advanced Cardiac Treatments Revolutionizing care from minimally invasive surgery to comprehensive outpatient services
King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its position as a regional leader in advanced cardiac care. Its Heart Centre combines cutting-edge technology with exceptional outcomes, making it the top choice for patients from Saudi Arabia, the MENA region, and beyond. Participating at Arab Health 2025, KFSHRC overviewed the Heart Centre's ground-breaking milestones that have redefined the landscape of cardiac care. These include performing the world's first fully robotic heart transplant in September 2024 through a novel procedure that minimizes complications and shortens recovery times, setting a global benchmark for minimally invasive surgery. Furthering this legacy, in January 2025, the Centre conducted the world's first robotic-assisted artificial heart pump implantation (HeartMate3), significantly improving recovery metrics and showcasing the transformative potential of robotic-assisted techniques. Since the launch of its Robotic Cardiac Surgery Program in 2019, the Heart Centre has performed over 400 robotic surgeries with an impressive 98% survival rate. In 2024, outpatient visits rose by 32.2%, and new patient acceptance increased by 4.6%, reflecting the growing trust in the Centre's ability to manage complex cases while maintaining exceptional patient outcomes. Following these achievements, KFSHRC's Heart Centre has become a premier destination for international patients seeking advanced cardiac treatments. In 2024 alone, KFSHRC treated patients from 17 countries, reflecting its growing reputation as a global leader in specialized healthcare. King Faisal Specialist Hospital and Research Centre is a 2443-bed tertiary/quaternary care hospital with facilities in Riyadh, Jeddah, and Madinah in the Kingdom of Saudi Arabia. It has over 17,000 employees from over 63 nationalities. KFSHRC specialises in inpatient and outpatient medical care, with excellent centres in Oncology, Organ Transplantation, Cardiovascular Diseases, Neurosciences, and Genetic Diseases. It is recognised and ranked globally as one of the top hospitals, as on Newsweek's and Brand Finance's World's Best Hospitals—Top 250 lists. KFSHRC's International Services adhere to the highest global standards, reflected in the performance of 5K+ bone marrow and 4K+ solid organ transplants, 3K+ robotic-assisted procedures, 2K+ submitted cardiovascular inpatients annually, and much more.
